by Drug Target Review –
Cell and gene therapy (CGT) is advancing rapidly, offering new treatments for complex conditions such as cancer and genetic disorders. As these therapies evolve, the demand for more efficient and reliable methods of cell expansion – an essential step in CGT manufacturing – becomes increasingly critical.
To facilitate this important process, the Biomedical division of PHC Corporation (PHC) has developed a cell expansion bioreactor system – a technology that is set to impact the future of CGT. Dr Tia Harmon manages the CGT portfolio for PHC Corporation of North America (PHCNA) and is passionate about how these technologies can empower researchers and accelerate CGT development.
